GlassScriptPhysician profile
Tom Nokham Baccam
NPI 1134145220
$1,354.71
in general payments reported to CMS, 2019-2025
19 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $68.66 · 2021: $17.63 · 2022: $171 · 2023: $442 · 2024: $226 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.21 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $338.17 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $281.38 | 2019-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.43 | 2023 | Jardiance |
| Astellas Pharma US INC | $122.93 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $99.31 | 2019-2025 | Airsupra |
| Amgen INC. | $68.88 | 2025 | Repatha, Otezla |
| Corium, LLC | $49.67 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $48.99 | 2022-2023 | Eliquis |
| Pfizer INC. | $31.54 | 2022-2024 | |
| Sanofi Pasteur INC. | $26.00 | 2023 | |
| Boston Scientific Corporation | $21.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.33 | 2019 | |
| Allergan, INC. | $19.29 | 2020 | |
| Viatris Specialty LLC | $19.12 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $17.63 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $14.91 | 2019 | |
| Tactile Systems Technology INC | $14.65 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.62 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Baccam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.